PATENT CLAIM ANALYSIS

Application Number: 16123912
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["546", "152000"]

Abstract:
Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

Claim (Index 5):
The combination of  claim 2 , wherein said additional therapeutic agent is ipilimumab.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 97.0
- Lexical Diversity: 1.48718
- Patent Class: 546.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15469707', '14933879', '15422118', '14933863', '15400748']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8101802608698206
- 35 USC 102 Novelty (BERT): 0.5391915000405002
- Combined Prediction Score: 0.7830813847868886
- Mean Citation Score: 324.800176
- Max Citation Score: 391.13113
- Similarity Product: 273.495102146104

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test